Advances in the Treatment of Recurrent Ovarian Cancer and Rare Malignant Ovarian Germ Cell Tumors
Search for other papers by Joyce F. Liu in
Current site
Google Scholar
PubMed
Search for other papers by Daniela E. Matei in
Current site
Google Scholar
PubMed
Most patients with epithelial ovarian cancer will experience recurrence. Treatment at the time of recurrence is largely guided by platinum sensitivity, symptom burden, prior toxicities, and patient preferences. For patients with a first platinum-sensitive recurrence, platinum-based doublets remain the preferred treatment approach. However, changes to care in the United States include the withdrawal of FDA approvals for PARP inhibitors in the recurrent setting for patients without BRCA-mutated disease. The treatment landscape has expanded with the approval of 2 antibody–drug conjugates—mirvetuximab soravtansine-gynx and fam-trastuzumab deruxtecan-nxki—which represent an exciting new class of therapeutics in the oncology pipeline. In contrast, for the rare malignant ovarian germ cell tumors, recurrence is uncommon and cure with up-front treatment is likely. Although progress in this subtype has been slower, treatment in this area is advancing.
Disclosures: Dr. Liu has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo, Eisai Inc., Genentech, Inc., GSK plc, and Zentalis Pharmaceuticals, Inc. Dr. Matei has disclosed receiving consulting fees from CVS Health Corporation and GSK plc; and receiving grant/research support from Acrivon Therapeutics, Eisai Inc., Merck & Co., Inc., Pinotbio Inc., and Shattuck Labs.
© 2019-2024 National Comprehensive Cancer Network